35 results on '"Katsi, Vasiliki"'
Search Results
2. Exercise and cardiac rehabilitation in hypertensive patients with heart failure with preserved ejection fraction: A position statement on behalf of the Working Group of Arterial Hypertension of the Hellenic Society of Cardiology.
- Author
-
Kallistratos M, Konstantinidis D, Dimitriadis K, Sanidas E, Katsi V, Androulakis E, Vlachopoulos C, Toutouzas K, Kanakakis J, Sideris S, Kafkas N, Mavrogianni AD, Papadopoulos CH, Stefanidis A, Patsourakos N, Kachrimanidis I, Papaioannou N, Tsioufis C, Kochiadakis G, and Marketou M
- Subjects
- Humans, Quality of Life, Stroke Volume, Exercise, Heart Failure, Cardiac Rehabilitation, Hypertension complications, Hypertension epidemiology, Cardiology
- Abstract
Arterial hypertension is a major cause of cardiovascular morbidity and mortality and the most common cause of comorbidity in heart failure (HF) with preserved ejection fraction (HFpEF). As an adjunct to medication, healthy lifestyle modifications with emphasis on regular exercise are strongly recommended by both the hypertension and the HF guidelines of the European Society of Cardiology. Several long-term studies have shown that exercise is associated with a reduction in all-cause mortality, a favorable cardiac and metabolic risk profile, mental health, and other non-cardiovascular benefits, as well as an improvement in overall quality of life. However, the instructions for the prescriptive or recommended exercise in hypertensive patients and, more specifically, in those with HFpEF are not well defined. Moreover, the evidence is based on observational or small randomized studies, while well-designed clinical trials are lacking. Despite the proven benefit and the guidelines' recommendations, exercise programs and cardiac rehabilitation in patients with hypertensive heart disease and HFpEF are grossly underutilized. This position statement provides a general framework for exercise and exercise-based rehabilitation in patients with hypertension and HFpEF, guides clinicians' rehabilitation strategies, and facilitates clinical practice. It has been endorsed by the Working Group of Arterial Hypertension of the Hellenic Society of Cardiology and is focused on the Health Care System in Greece., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
3. Current Management of Hypertension in Older Adults.
- Author
-
Chatzis DG, Magounaki K, Pantazopoulos I, Beltsios ET, Katsi V, and Tsioufis KP
- Subjects
- Humans, Aged, Blood Pressure, Risk Factors, Aging, Antihypertensive Agents therapeutic use, Hypertension drug therapy
- Abstract
Hypertension is a major global health issue and it accounts for a big proportion of disability and mortality worldwide even in adults aged 65 years and above. Moreover, advanced age per se is an independent risk factor for adverse cardiovascular events and there is abundant scientific evidence supporting the beneficial effects of blood pressure lowering, within certain limits, in this subset of hypertensive patients. The aim of this review article is to summarize the available evidence regarding the appropriate management of hypertension in this specific subgroup, in an era of a constantly increasing aging population., (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2023
- Full Text
- View/download PDF
4. Beta-Blockers in Pregnancy: Clinical Update.
- Author
-
Katsi V, Papakonstantinou IP, Papazachou O, Makris T, and Tsioufis K
- Subjects
- Infant, Newborn, Pregnancy, Female, Humans, Fetal Growth Retardation drug therapy, Adrenergic beta-Antagonists adverse effects, Antihypertensive Agents adverse effects, Hypertension drug therapy, Hypertension, Pregnancy-Induced drug therapy, Pregnancy Complications
- Abstract
Purpose of Review: The aim of this review was to determine the anticipated benefits and adverse effects of beta-blockers in pregnant women with hypertension. The other issue was to assess the possible adverse effects of beta-blockers for their babies and provide current consensus recommendations for appropriate selection and individualized antihypertensive treatment with beta-blockers in pregnancy-associated hypertension., Recent Findings: Hypertensive disorders of pregnancy are a major cause of maternal and fetal morbidity, with consequences later in life. Certain beta-blockers are useful for ameliorating hypertension in pregnancy and may have a protective role in endothelial dysfunction. However, some aspects of beta-blocker use in pregnancy are contentious among providers. Evidence on their safety, although well documented, is variable, and recent research reveals areas of controversy. Besides intrauterine growth restriction, other neonatal and obstetric complications remain a concern and should be explored thoroughly. Attention is necessary when treating pregnancy-associated hypertensive disorders with beta-blockers. Specific beta-blockers are considered safe in pregnancy, although the associated effects in the fetus are not clearly known and evidence is lacking for many safety outcomes, other than intrauterine growth restriction. Nevertheless, beta-blockers with specific indications in pregnancy under individualized selection and monitoring may confer substantial improvements in pregnant women with hypertension., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
5. Opportunistic screening for hypertension: what does it say about the true epidemiology?
- Author
-
Menti A, Kalpourtzi N, Gavana M, Vantarakis A, Voulgari PV, Hadjichristodoulou C, Gkaliagkousi E, Doumas M, Kalaitzidis RG, Kallistratos MS, Karakosta A, Katsi V, Krokidis X, Manios E, Marketou M, Ntineri A, Papadakis JA, Papadopoulos D, Sarafidis P, Trypsianis G, Chatzopoulos M, Chlouverakis G, Alamanos Y, Zebekakis P, Touloumi G, and Stergiou GS
- Subjects
- Adult, Antihypertensive Agents pharmacology, Antihypertensive Agents therapeutic use, Blood Pressure, Cross-Sectional Studies, Female, Humans, Male, Reproducibility of Results, Hypertension diagnosis, Hypertension drug therapy, Hypertension epidemiology
- Abstract
This study aimed to assess the reliability of opportunistic screening programs in estimating the prevalence, treatment, and control rate of hypertension in the general population. Two recent epidemiological surveys obtained data on hypertension in the adult general population in Greece. The EMENO (2013-2016) applied a multi-stage stratified random sampling method to collect nationwide data. The MMM (2019) collected data through opportunistic (voluntary) screening in five large cities. Hypertension was defined as blood pressure (BP) ≥ 140/90 mmHg (single occasion; average of 2nd-3rd measurement; electronic devices) and/or use of antihypertensive drugs. Data from a total of 10,426 adults were analyzed (EMENO 4,699; MMM 5,727). Mean age (SD) was 49.2 (18.6)/52.7 (16.6) years (EMENO/MMM, p < 0.001), men 48.6/46.5% (p < 0.05) and body mass index 28.2 (5.7)/27.1 (5.0) kg/m
2 (p < 0.001). The prevalence of hypertension in ΕΜΕΝΟ/MMM was 39.6/41.6% (p < 0.05) and was higher in men (42.7/50.9%, p < 0.001) than in women (36.5/33.6%, p < 0.05). Among hypertensive subjects, unaware were 31.8/21.3% (EMENO/MMM, p < 0.001), aware untreated 2.7/5.6% (p < 0.001), treated uncontrolled 35.1/24.8% (p < 0.001), and treated controlled 30.5/48.3% (p < 0.001). In conclusion, the prevalence of hypertension was similar with random sampling (EMENO) and opportunistic screening (MMM). However, opportunistic screening underestimated the prevalence of undiagnosed hypertension and overestimated the rate of hypertension treatment and control. Thus, random sampling national epidemiological studies are necessary for assessing the epidemiology of hypertension. Screening programs are useful for increasing awareness of hypertension in the general population, yet the generalization of such findings should be interpreted with caution., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2022
- Full Text
- View/download PDF
6. Management of Hypertension and Blood Pressure Dysregulation in Patients with Parkinson's Disease-a Systematic Review.
- Author
-
Katsi V, Papakonstantinou I, Solomou E, Antonopoulos AS, Vlachopoulos C, and Tsioufis K
- Subjects
- Blood Pressure, Humans, Quality of Life, Hypertension complications, Hypertension drug therapy, Hypotension, Orthostatic etiology, Parkinson Disease complications
- Abstract
Purpose of Review: The aim of this review article was to summarize the cardiovascular and blood pressure profile regarding Parkinson disease patients and to provide an update on the recent advancements in the field of the diagnosis and management of blood pressure abnormalities in these patients. Our goal was to guide physicians to avoid pitfalls in current practice while treating patients with Parkinson disease and blood pressure abnormalities. For this purpose, we searched bibliographic databases (PubMed, Google Scholar) for all publications published on blood pressure effects in Parkinson disease until May 2020. Furthermore, we highlight some thoughts and potential perspectives for the next possible steps in the field., Recent Findings: Blood pressure dysregulation in patients with Parkinson's disease has several implications in clinical practice and presents an ongoing concern. Compared with chronic essential hypertension, the syndrome of combined neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease has received little attention. If left untreated, hypertension may lead to cardiovascular disease whereas hypotension may lead to fall-related complications, with tremendous impact on the quality of life of affected individuals. The effect of blood Epressure control and the risk of death from cardiovascular disease in Parkinson disease are largely unexplored. Blood pressure abnormalities in Parkinson disease present bidirectional relationship and the rationale for treating and controlling hypertension in persons with Parkinson disease and concurrent neurogenic orthostatic hypotension and/or supine hypertension is compelling. Further research is warranted in order to clarify the mechanisms, clinical implications, and potential reversibility of compromised cardiovascular function, in persons with Parkinson disease.
- Published
- 2021
- Full Text
- View/download PDF
7. Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review.
- Author
-
Katsi V, Michalakeas C, Soulaidopoulos S, Antonopoulos AS, Vlachopoulos C, Tousoulis D, and Tsioufis K
- Subjects
- Angiotensin II Type 1 Receptor Blockers adverse effects, Antihypertensive Agents adverse effects, Benzimidazoles, Blood Pressure, Drug Therapy, Combination, Humans, Oxadiazoles, Treatment Outcome, Uric Acid, Chlorthalidone adverse effects, Hypertension diagnosis, Hypertension drug therapy
- Abstract
Background: Azilsartan medoxomil (AZM) is the newest representative in the class of angiotensin receptor blockers. Azilsartan medoxomil in combination with the older diuretic chlorthalidone (CLD) in fixed-doses of AZM/CLD 40/12.5 mg and 40/25 mg has been approved by the FDA for use in patients with essential hypertension. We sought to evaluate the safety and tolerability of AZL-M alone and in combination with CLD., Methods: We conducted a search in PubMed using the keywords 'azilsartan', 'azilsartan medoxomil', 'chlorthalidone, 'safety', 'tolerability' in order to find scientific studies evaluating the safety of these drugs. We included studies reporting side effects of these drugs, alone or in combination, in comparison to placebo or other antihypertensive medications. For our systematic review, we followed the PRISMA guidelines., Results: Azilsartan medoxomil is a potent antihypertensive medicine with an acceptable safety profile. The most commonly reported adverse events are dizziness, headache, fatigue, upper respiratory tract infection and urinary tract infection. Chlorthalidone is more potent and has a considerably longer duration of action than the most commonly prescribed diuretic hydrochlorothiazide. Safety and tolerability between these two drugs are similar except higher serum uric acid and lower potassium levels with chlorthalidone., Conclusion: The combination of azilsartan medoxomil with chlorthalidone has been shown to be effective in lowering blood pressure with an acceptable safety and tolerability profile. This fixeddose combination is an attractive treatment option for hypertension management., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2021
- Full Text
- View/download PDF
8. Blood-brain barrier dysfunction: the undervalued frontier of hypertension.
- Author
-
Katsi V, Marketou M, Maragkoudakis S, Didagelos M, Charalambous G, Parthenakis F, Tsioufis C, and Tousoulis D
- Subjects
- Adult, Antihypertensive Agents, Blood-Brain Barrier, Cognition, Humans, Cognitive Dysfunction, Hypertension
- Abstract
The blood-brain barrier (BBB) constitutes the complex anatomic and physiologic interface between the intravascular compartment and the central nervous system, and its integrity is paramount for the maintenance of the very sensitive homeostasis of the central nervous system. Arterial hypertension is a leading cause of morbidity and mortality. The BBB has been shown to be disrupted in essential hypertension. BBB integrity is important for central autonomic control and this may be implicated in the pathophysiology of hypertension. On the other hand, evidence from experimental studies indicates that BBB disruption can be present in both hypertensive disease and dementia syndromes, suggesting a possibly key position of loss of BBB integrity in the pathophysiological pathways linking arterial hypertension with cognitive decline. Although much still remains to be elucidated with respect to the exact underlying mechanisms, the discovery of novel pathological pathways has changed our understanding of adult dementia and central nervous system disease overall, pointing out-in parallel-new potential therapeutic targets. The aim of this review is to summarize current scientific knowledge relevant to the pathophysiologic pathways that are involved in the disruption of the BBB function and potentially mediate hypertension-induced cognitive impairment. In parallel, we underline the differential cognition-preserving effect of several antihypertensive agents of similar blood pressure-lowering capacity, highlighting the presence of previously under-recognized BBB-protective actions of these drugs.
- Published
- 2020
- Full Text
- View/download PDF
9. Arterial hypertension in patients under antineoplastic therapy: a systematic review.
- Author
-
Katsi V, Magkas N, Georgiopoulos G, Athanasiadi E, Virdis A, Masi S, Kliridis P, Hatziyanni A, Tsioufis C, and Tousoulis D
- Subjects
- Antihypertensive Agents therapeutic use, Humans, Hypertension complications, Hypertension drug therapy, Hypertension epidemiology, Incidence, Neoplasms drug therapy, Neoplasms epidemiology, Risk Factors, Vascular Endothelial Growth Factor A antagonists & inhibitors, Antineoplastic Agents adverse effects, Hypertension chemically induced, Neoplasms complications
- Abstract
Background: Cardio-oncology aims to mitigate adverse cardiovascular manifestations in cancer survivors, but treatment-induced hypertension or aggravated hypertension has received less attention in these high cardiovascular risk patients., Methods: In this systematic review, we searched literature for contemporary data on the prevalence, pathophysiologic mechanisms, treatment implications and preventive strategies of hypertension in patients under antineoplastic therapy., Results: Several classes of antineoplastic drugs, including mainly vascular endothelial growth factor inhibitors, proteasome inhibitors, cisplatin derivatives, corticosteroids or radiation therapy were consistently associated with increased odds for new-onset hypertension or labile hypertensive status in previous controlled patients. Moreover, hypertension constitutes a major risk factor for chemotherapy-induced cardiotoxicity, which is the most serious cardiovascular adverse effect of antineoplastic therapy. Despite the heterogeneity of pooled studies, the pro-hypertensive profile of examined drug classes could be attributed to common structural and functional disorders. Importantly, certain antihypertensive drugs are considered to be more effective in the management of hypertension in this population and may partially attenuate indirect complications of cancer treatment, such as progressive development of cardiomyopathy and/or cardiovascular death. Nonpharmacological approaches to alleviate hypertension in cancer patients are also described, albeit adjudicated as less effective in general., Conclusion: A growing body of evidence suggests that multiple antineoplastic agents increase the rate of progression of hypertension. Physicians need to balance the life-saving cancer treatment and the inflated risk of adverse cardiovascular events due to suboptimal management of hypertension in order to achieve improved clinical outcomes and sustained survival for their patients.
- Published
- 2019
- Full Text
- View/download PDF
10. The Role of Arterial Hypertension in Mitral Valve Regurgitation.
- Author
-
Katsi V, Georgiopoulos G, Magkas N, Oikonomou D, Virdis A, Nihoyannopoulos P, Toutouzas K, and Tousoulis D
- Subjects
- Adrenergic beta-Antagonists therapeutic use, Antihypertensive Agents therapeutic use, Humans, Ventricular Remodeling, Hypertension complications, Hypertension drug therapy, Mitral Valve Insufficiency complications
- Abstract
Purpose of Review: To review medical literature for evidence of association between hypertension and mitral regurgitation (MR) and summarize potential favorable effects of antihypertensive drugs on MR natural history and treatment., Recent Findings: Hypertension and MR are common diseases affecting a large proportion of the general population. Contemporary evidence suggests that hypertension may worsen the progression and prognosis of MR through augmented mechanical stress and increased regurgitation volume. Renin-angiotensin axis inhibitors, beta-blockers, and vasodilators have been tested in order to prevent or decrease primary or secondary MR. Although antihypertensive agents may improve hemodynamic parameters and left ventricular remodeling in primary MR, there is no strong evidence of benefit on clinical outcomes. On the other hand, a beneficial effect of these drugs on secondary MR is better established. Moreover, there are no studies evaluating a possible benefit of lower blood pressure targets in MR. Randomized controlled trials are warranted to elucidate the precise role of antihypertensive therapy on treatment of MR.
- Published
- 2019
- Full Text
- View/download PDF
11. GUT Microbiome-GUT Dysbiosis-Arterial Hypertension: New Horizons.
- Author
-
Katsi V, Didagelos M, Skevofilax S, Armenis I, Kartalis A, Vlachopoulos C, Karvounis H, and Tousoulis D
- Subjects
- Animals, Antihypertensive Agents therapeutic use, Bacteria drug effects, Disease Models, Animal, Dysbiosis, Host-Pathogen Interactions, Humans, Hypertension drug therapy, Hypertension epidemiology, Probiotics therapeutic use, Risk Factors, Arterial Pressure drug effects, Bacteria growth & development, Gastrointestinal Microbiome drug effects, Hypertension microbiology, Hypertension physiopathology, Intestines microbiology
- Abstract
Arterial hypertension is a progressive cardiovascular syndrome arising from complex and interrelated etiologies. The human microbiome refers to the community of microorganisms that live in or on the human body. They influence human physiology by interfering in several processes such as providing nutrients and vitamins in Phase I and Phase II drug metabolism. The human gut microbiota is represented mainly by Firmicutes and Bacteroidetes and to a lesser degree by Actinobacteria and Proteobacteria, with each individual harbouring at least 160 such species. Gut microbiota contributes to blood pressure homeostasis and the pathogenesis of arterial hypertension through production, modification, and degradation of a variety of microbial-derived bioactive metabolites. Animal studies and to a lesser degree human research has unmasked relative mechanisms, mainly through the effect of certain microbiome metabolites and their receptors, outlining this relationship. Interventions to utilize these pathways, with probiotics, prebiotics, antibiotics and fecal microbiome transplantation have shown promising results. Personalized microbiome-based disease prediction and treatment responsiveness seem futuristic. Undoubtedly, a long way of experimental and clinical research should be pursued to elucidate this novel, intriguing and very promising horizon., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2019
- Full Text
- View/download PDF
12. The Role of Angiotensin-(1-7)/Mas Axis and Angiotensin Type 2 Receptors in the Central Nervous System in Cardiovascular Disease and Therapeutics: A Riddle to be Solved.
- Author
-
Katsi V, Maragkoudakis S, Marketou M, Tsioufis C, Parthenakis F, and Tousoulis D
- Subjects
- Angiotensin II Type 2 Receptor Blockers therapeutic use, Animals, Antihypertensive Agents therapeutic use, Baroreflex, Blood Pressure, Central Nervous System drug effects, Central Nervous System physiopathology, Humans, Hypertension drug therapy, Hypertension physiopathology, Proto-Oncogene Mas, Receptor, Angiotensin, Type 2 drug effects, Sympathetic Nervous System drug effects, Angiotensin I metabolism, Cardiovascular System innervation, Central Nervous System metabolism, Hypertension metabolism, Peptide Fragments metabolism, Proto-Oncogene Proteins metabolism, Receptor, Angiotensin, Type 2 metabolism, Receptors, G-Protein-Coupled metabolism, Renin-Angiotensin System drug effects, Sympathetic Nervous System physiopathology
- Abstract
In recent years, the Angiotensin-(1-7)/Mas receptor [Ang-(1-7)/Mas] sub-branch of the Renin-Angiotensin System (RAS) in the brain, and Angiotensin Type 2 Receptors (AT2R), have attracted scientific interest, as there is evidence that they constitute an essential pathway in cardiovascular regulation, in health and in disease. By acting centrally, the Ang-(1-7)/Mas axis - that has been termed 'the axis of good'- can exert blood pressure-lowering effects, while also favourably altering baroreflex sensitivity and noradrenergic neurotransmission. Thus, research has focused on the possible neuro- and cardioprotective effects of this pathway in the setting of cardiovascular disease, ultimately aiming to evaluate the potential for development of novel therapeutic strategies based on its modulation. We summarize the available evidence from experimental studies in this context, aiming to assess current limits of scientific knowledge relevant to this newly-described 'player' in haemodynamic regulation, that may become a potential therapeutic target., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2019
- Full Text
- View/download PDF
13. Azilsartan and Chlorthalidone-new Powerful Fixed dose Antihypertensive Combination.
- Author
-
Katsi V, Athanasiadi E, Tsioufis C, and Tousoulis D
- Subjects
- Angiotensin Receptor Antagonists adverse effects, Antihypertensive Agents adverse effects, Benzimidazoles adverse effects, Chlorthalidone adverse effects, Diuretics adverse effects, Drug Combinations, Humans, Hypertension diagnosis, Hypertension physiopathology, Oxadiazoles adverse effects, Treatment Outcome, Angiotensin Receptor Antagonists therapeutic use, Antihypertensive Agents therapeutic use, Arterial Pressure drug effects, Benzimidazoles therapeutic use, Chlorthalidone therapeutic use, Diuretics therapeutic use, Hypertension drug therapy, Oxadiazoles therapeutic use
- Abstract
Arterial hypertension is a disease that still affects a major part of the population worldwide, and leads to fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. From the CDC statistical analysis, as regarding to United States, 1 of every 3 adults has high blood pressure, and οnly about half (54%) of them have it under control. Furthermore, all that leads to a nation cost about $46 billion each year. Efforts to find new ways to regulate arterial hypertension are therefore imperative. In our days, a lot of references have been made to the use of a new therapeutic combination, that of azilsartan - an innovative ARB, in combination with chlorthalidone. Ιn fact, it is a combination now prescribed in a number of countries. A significant number of trials shows both azilsartan vs popular antihypertensive drugs, as well as chlorthalidone vs chlorothiazide, to present a better antihypertensive effect. This effect is even greater when the two substances are combined. In this article, we will try to present the latest findings concerning the efficacy, safety and clinical utility of this combination, as well as its adverse events, in comparison with other widely used therapeutic options., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
- Published
- 2018
- Full Text
- View/download PDF
14. The emerging role of Cardiovascular Magnetic Resonance in the evaluation of hypertensive heart disease.
- Author
-
Mavrogeni S, Katsi V, Vartela V, Noutsias M, Markousis-Mavrogenis G, Kolovou G, and Manolis A
- Subjects
- Early Diagnosis, Heart Diseases etiology, Heart Diseases physiopathology, Heart Diseases therapy, Humans, Hypertension diagnosis, Hypertension physiopathology, Predictive Value of Tests, Prognosis, Reproducibility of Results, Heart Diseases diagnostic imaging, Hypertension complications, Magnetic Resonance Imaging
- Abstract
Background: Arterial hypertension is the commonest cause of cardiovascular death. It may lead to hypertensive heart disease (HHD), including heart failure (HF), ischemic heart disease (IHD) and left ventricular hypertrophy (LVH)., Main Body: According to the 2007 ESH/ESC guidelines, the recommended imaging technique is echocardiography (echo), when a more sensitive detection of LVH than that provided by ECG, is needed. Cardiovascular Magnetic Resonance (CMR), a non-invasive, non-radiating technique, offers the following advantages, beyond echo: a) more reliable and reproducible measurements of cardiac parameters such as volumes, ejection fraction and cardiac mass b) more accurate differentiation of LVH etiology by providing information about tissue characterisation c) more accurate evaluation of myocardial ischemia, specifically if small vessels disease is present d) technique of choice for diagnosis of renovascular, aortic tree/branches lesions and quantification of aortic valve regurgitation e) technique of choice for treatment evaluation in clinical trials. The superiority of CMR against echocardiography in terms of reproducibility, operator independency, unrestricted field of view and capability of tissue characterization makes the technique ideal for evaluation of heart, quantification of aortic valve regurgitation, aorta and aortic branches., Conclusions: CMR has a great potential in early diagnosis, risk stratification and treatment follow up of HHD. However, an international consensus about CMR in HHD, taking under consideration the cost-benefit ratio, expertise and availability, is still warranted.
- Published
- 2017
- Full Text
- View/download PDF
15. A case of aortic arch coarctation, bicuspid aortic valve and aortic sinus aneurysm in an adult with moderate hypertension.
- Author
-
Chrysohoou C, Katsi V, Trikalinos N, Tzifa A, Alexopoulos N, Brili S, Nihoyiannopoulos P, and Tousoulis D
- Subjects
- Adult, Aneurysm diagnostic imaging, Aneurysm pathology, Angiography methods, Aorta, Thoracic pathology, Aortic Coarctation surgery, Aortic Valve diagnostic imaging, Bicuspid Aortic Valve Disease, Echocardiography methods, Humans, Hypertension complications, Male, Sinus of Valsalva diagnostic imaging, Sinus of Valsalva pathology, Stents standards, Treatment Outcome, Aorta, Thoracic diagnostic imaging, Aortic Coarctation diagnostic imaging, Aortic Valve abnormalities, Heart Valve Diseases diagnostic imaging, Hypertension drug therapy, Magnetic Resonance Angiography methods
- Published
- 2017
- Full Text
- View/download PDF
16. Effects of Oral and Non-Insulin Injectable Antidiabetic Treatment in Hypertension: A Systematic Review.
- Author
-
Katsi V, Georgiopoulos G, Vogiatzi G, Oikonomou D, Megapanou M, Skoumas J, Vlachopoulos C, Nihoyannopoulos P, and Tousoulis D
- Subjects
- Administration, Oral, Animals, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 metabolism, Humans, Hypertension epidemiology, Hypertension metabolism, Injections, Subcutaneous, Treatment Outcome, Antihypertensive Agents administration & dosage, Diabetes Mellitus, Type 2 drug therapy, Hypertension drug therapy, Hypoglycemic Agents administration & dosage
- Abstract
Background: Diabetes mellitus type 2 (T2DM) often co-exists with hypertension, and this aggregation of co-morbidities amplifies the risk for future cardiovascular events. Therefore, it appears crucial to understand the essence of choosing oral and non-insulin injectable anti-diabetic drugs (ADs) with a favorable hemodynamic impact that could partially attenuate the increased baseline cardiovascular risk., Objective: We sought to evaluate the effect of ADs on blood pressure (BP) indices and to assess the potential role of certain ADs towards hypertension treatment., Method: We performed a systematic review of the literature searching MEDLINE via Pubmed for all human studies implementing ADs, either individually or in combinations., Results: Metformin was found to reduce BP in small cohorts but failed to confirm its beneficial effect in a metaanalysis of 41 studies. Thiazolidinediones are associated with BP lowering but are contraindicated in patients with heart failure. Sulfonylureas, on the other hand, may increase BP, while a-glucosidase inhibitors, DPP-4 inhibitors, and SGLT2 inhibitors activate favorable pathophysiologic mechanisms serving as potential BP lowering agents. Relevant BP reduction was established for GLP-1 Ras in most clinical trials., Conclusion: The favorable hemodynamic impact of certain classes of ADs might provide synergistic or incremental therapeutic benefits in high-risk patients suffering from both T2DM and hypertension. Additional randomized trials designed under the hypothesis of the emerging beneficial hemodynamic effect of ADs are expected to provide more robust evidence and to guide the optimization of combined treatment strategies in this challenging group of patients., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
- Published
- 2017
- Full Text
- View/download PDF
17. Essential hypertension in the pathogenesis of age-related macular degeneration: a review of the current evidence.
- Author
-
Katsi VK, Marketou ME, Vrachatis DA, Manolis AJ, Nihoyannopoulos P, Tousoulis D, Vardas PE, and Kallikazaros I
- Subjects
- Antihypertensive Agents therapeutic use, Essential Hypertension, Humans, Hypertension drug therapy, Hypertension physiopathology, Renin-Angiotensin System, Risk Factors, Hypertension complications, Macular Degeneration epidemiology, Macular Degeneration etiology
- Abstract
Age-related macular degeneration (AMD) is one of the main causes of vision loss, especially in the elderly. The involvement of essential hypertension in its pathogenesis has been well covered in the literature since it was first recognized. Hemodynamic abnormalities appear to contribute to AMD, with the renin-angiotensin system playing a significant role. Many studies have demonstrated that high blood pressure is associated with lower choroidal blood flow and disturbed vascular homeostasis in these patients. In addition, AMD is characterized by abnormal neovascularization, to which angiotensin II and growth factors make a large contribution. Most epidemiological studies have found essential hypertension to be a risk factor for AMD. However, although all agree that the strongest predisposing factors are age and smoking, overall there is some inconsistency regarding the exact role of hypertension in its pathogenesis. In particular, there are no data in the literature to support the view that antihypertensive medication and the successful management of hypertension have a positive effect on the clinical outcome of AMD. This reinforces the data indicating that the cause of AMD is multifactorial and suggests that, although essential hypertension probably plays a role, in itself it is unlikely to be a major contributor to the future occurrence of AMD.
- Published
- 2015
- Full Text
- View/download PDF
18. Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?
- Author
-
Katsi V, Skalis G, Pavlidis AN, Makris T, Nihoyannopoulos P, Tousoulis D, and Kallikazaros I
- Subjects
- Angiotensin Receptor Antagonists therapeutic use, Biphenyl Compounds, Drug Combinations, Humans, Hypertension physiopathology, Neprilysin, Treatment Outcome, Valsartan, Aminobutyrates therapeutic use, Blood Pressure drug effects, Hypertension drug therapy, Tetrazoles therapeutic use
- Abstract
The need for novel antihypertensive therapies represents a continuous challenge. LCZ696 is a first-in-class angiotensin receptor neprilysin inhibitor that has been shown to enhance endogenous natriuretic peptide (NP) actions on neurohormonal activation. This effect seems to be additive to that of the renin-angiotensin-aldosterone system (RAAS) suppression, as impressively suggested in the PARADIGM HF study. LCZ696 has been shown to be effective in reducing blood pressure in several small studies; however, its effectiveness and safety remain to be proved in larger studies. This review summarizes the role of RAAS and NP system in the pathophysiology of hypertension and reviews the current data on the antihypertensive effects of LCZ696., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
19. Epigenetics, the missing link in hypertension.
- Author
-
Raftopoulos L, Katsi V, Makris T, Tousoulis D, Stefanadis C, and Kallikazaros I
- Subjects
- Humans, RNA, Untranslated genetics, DNA Methylation physiology, Epigenesis, Genetic physiology, Histones metabolism, Hypertension physiopathology, Models, Biological, RNA, Untranslated metabolism
- Abstract
Epigenetics refers to functional alterations in gene expression or phenotype without any change of the underlying DNA sequence. It is the study of the potential of a cell or organism to express different traits through functional regulation of its gene transcription. Though it is met as a necessary process in biology, epigenetics may often play a crucial part in the development of specific pathologic conditions, including cardiovascular diseases and hypertension., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
20. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: a systematic review and meta-analysis.
- Author
-
Varounis C, Katsi V, Kallikazaros IE, Tousoulis D, Stefanadis C, Parissis J, Lekakis J, Siristatidis C, Manolis AJ, and Makris T
- Subjects
- Humans, Hypertension epidemiology, Observational Studies as Topic, Randomized Controlled Trials as Topic methods, Sleep Apnea, Obstructive epidemiology, Treatment Outcome, Blood Pressure physiology, Continuous Positive Airway Pressure methods, Hypertension physiopathology, Hypertension therapy, Sleep Apnea, Obstructive physiopathology, Sleep Apnea, Obstructive therapy
- Published
- 2014
- Full Text
- View/download PDF
21. The association of Restless Legs Syndrome with hypertension and cardiovascular disease.
- Author
-
Katsi V, Katsimichas T, Kallistratos MS, Tsekoura D, Makris T, Manolis AJ, Tousoulis D, Stefanadis C, and Kallikazaros I
- Subjects
- Humans, Restless Legs Syndrome epidemiology, Restless Legs Syndrome physiopathology, Cardiovascular Diseases complications, Hypertension complications, Restless Legs Syndrome complications
- Abstract
Restless Legs Syndrome (RLS), is a sensory-motor neurological disorder that appears to be surprisingly common in the community. Periodic limb movements in sleep are typically encountered in more than 80% of RLS patients and comprise involuntary muscular jerks in the lower limbs, such as flexion of the knees or ankles. Iron deficiency and dopaminergic neuronal dysfunction in the central nervous system are currently thought to be the likely pathophysiological culprits. There is evidence linking RLS to hypertension and cardiovascular disease. This short review will first present a synopsis of epidemiological, clinical and pathophysiological data concerning the syndrome, and then information on the possible links between RLS and cardiovascular disorders.
- Published
- 2014
- Full Text
- View/download PDF
22. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
- Author
-
Katsi V, Zerdes I, Manolakou S, Makris T, Nihoyannopoulos P, Tousoulis D, and Kallikazaros I
- Subjects
- Animals, Humans, Hypertension diagnosis, Hypertension physiopathology, Hypertension prevention & control, Neoplasms blood supply, Neoplasms metabolism, Neoplasms pathology, Neovascularization, Pathologic, Risk Factors, Signal Transduction drug effects, Vascular Endothelial Growth Factor A metabolism, Angiogenesis Inhibitors adverse effects, Blood Pressure drug effects, Hypertension chemically induced, Neoplasms drug therapy, Vascular Endothelial Growth Factor A antagonists & inhibitors
- Abstract
The introduction of therapies that inhibit tumor angiogenesis and particularly target to vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) (VEGF inhibitors/VEGFi) have revolutionized the treatment of various cancer types. Although their clinical benefit can be optimal for cancer-affected patients, the safety of these targeted agents is of special concern especially for longer-term adjuvant or maintenance treatment. Importantly, VEGFi therapy has been significantly associated with hypertension (HTN) as an adverse effect and therefore the control of blood pressure (BP) after the administration of these drugs remains a challenging matter to be faced. The aim of this review is to summarize studies which investigate the association of VEGFi agents with HTN manifestation and the possible risks associated with this complication. Additionally, given that the optimal management of HTN caused by VEGFi remains obscure, this review will focus on prevention strategies including BP monitoring plans and propose potential therapeutic approaches.
- Published
- 2014
- Full Text
- View/download PDF
23. Novel antidepressant drugs, arterial hypertension and cardiovascular disease.
- Author
-
Katsi VK, Marketou M, Vamvakou G, Makris T, Tousoulis D, Stefanadis CI, Vardas P, and Kallikazaros IE
- Subjects
- Animals, Antidepressive Agents adverse effects, Bupropion adverse effects, Bupropion therapeutic use, Cardiovascular Diseases chemically induced, Cardiovascular System drug effects, Cyclohexanols adverse effects, Cyclohexanols therapeutic use, Humans, Hypertension chemically induced, Patents as Topic, Selective Serotonin Reuptake Inhibitors adverse effects, Selective Serotonin Reuptake Inhibitors therapeutic use, Venlafaxine Hydrochloride, Antidepressive Agents therapeutic use, Cardiovascular Diseases physiopathology, Hypertension physiopathology
- Abstract
Depression is a common mental health issue worldwide leading to disability, functional decline and increased mortality. Novel antidepressants have been developed during the last decades in order to treat depression syndromes. Some evidence suggests that major depression has been associated with the development of congestive heart failure and with adverse outcomes in patients with coronary heart disease. The purpose of the present article is to review the impact of novel antidepressant patent drugs on cardiovascular disease and arterial hypertension.
- Published
- 2013
- Full Text
- View/download PDF
24. Aggravation of left ventricular diastolic dysfunction in hypertensives with coronary artery disease.
- Author
-
Vlasseros I, Katsi V, Vyssoulis G, Pylarinos I, Richter D, Gialernios T, Souretis G, Tousoulis D, Stefanadis C, and Kallikazaros I
- Subjects
- Aged, Cohort Studies, Coronary Angiography, Coronary Artery Disease diagnosis, Coronary Artery Disease etiology, Electrocardiography, Female, Humans, Hypertension complications, Logistic Models, Male, Middle Aged, Predictive Value of Tests, Stroke Volume physiology, Coronary Artery Disease physiopathology, Diastole physiology, Hypertension physiopathology, Ventricular Dysfunction, Left physiopathology
- Abstract
We investigated the combined effects of hypertension and coronary artery disease (CAD) on left ventricular (LV) diastolic function. We examined 118 consecutive hypertensives who underwent diagnostic coronary angiography. All patients underwent a complete echocardiographic study within 24 h of catheterization by operators blind to their condition. The study participants were divided into two groups according to the presence of CAD: group A, with the disease (n=72); and group B, without (n=46). Patients with CAD exhibited lower LV fractional shortening and ejection fraction (P=0.002 and P=0.001). Hypertensives with CAD had significantly prolonged isovolumic relaxation time (IVRT) compared to those without CAD (P<0.001). Most interestingly, CAD patients had significantly worse Ema/Ama, Vp (flow propagation velocity), E/Vp and Vp/IVRT (all P<0.05). In addition, after adjusting for confounders, univariate and multivariate logistic regression analyses revealed that IVRT increases were associated with greater odds of CAD, whereas decreases in Vp or Vp/IVRT were associated with lower odds of CAD (all P ≤ 0.001). In hypertensives, the early recognition of LV diastolic performance alteration may be associated with the presence of significant CAD, indicating the need for more aggressive approaches both in terms of pharmacological treatment and interventional evaluation.
- Published
- 2013
- Full Text
- View/download PDF
25. Aortic valve stenosis and arterial hypertension: a synopsis in 2013.
- Author
-
Katsi V, Marketou M, Kallistratos MS, Makris T, Manolis AJ, Tousoulis D, Stefanadis C, Vardas P, and Kallikazaros I
- Subjects
- Animals, Antihypertensive Agents therapeutic use, Aortic Valve Stenosis diagnosis, Echocardiography methods, Humans, Prevalence, Aortic Valve Stenosis drug therapy, Aortic Valve Stenosis physiopathology, Hypertension physiopathology
- Abstract
Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. The pathophysiology of AVS shares some similarities with essential hypertension, which might be the link between the two diseases. Although AS is usually related with low blood pressure levels, approximately one third of patients with severe AS suffer from arterial hypertension, a percentage that can increase up to 50 % according some studies. This review will summarize various aspects regarding the prevalence the pathophysiology and the natural history of those two diseases that seems to be linked, as well as the effect of blood pressure and antihypertensive treatment on various echocardiographic parameters in patients with AVS.
- Published
- 2013
- Full Text
- View/download PDF
26. Impact of arterial hypertension on the eye.
- Author
-
Katsi V, Marketou M, Vlachopoulos C, Tousoulis D, Souretis G, Papageorgiou N, Stefanadis C, Vardas P, and Kallikazaros I
- Subjects
- Humans, Risk Factors, Eye Diseases etiology, Hypertension complications, Hypertensive Retinopathy etiology
- Abstract
Systemic hypertension has been linked to a wide range of major eye diseases. High arterial blood pressure (BP) decreases choroidal circulatory flow, increases intraocular pressure, and is associated with retinal microvascular abnormalities and prevalence of retinal vein occlusion (RVO) and retinopathy. This review offers a comprehensive overview of ocular diseases associated with hypertension and emphasizes their importance as predictors to future cardiovascular events. It also gives evidence-based clinical data for the therapeutic approach of eye disease in hypertensive patients.
- Published
- 2012
- Full Text
- View/download PDF
27. Association between retinal microcirculation and aortic stiffness in hypertensive patients.
- Author
-
Katsi V, Vlachopoulos C, Souretis G, Baou K, Dagalaki I, Alexopoulos N, Tousoulis D, Hatziyianni A, Stefanadis C, and Kallikazaros I
- Subjects
- Adult, Blood Flow Velocity physiology, Cohort Studies, Female, Humans, Hypertension diagnosis, Male, Middle Aged, Hypertension physiopathology, Hypertensive Retinopathy diagnosis, Hypertensive Retinopathy physiopathology, Microcirculation physiology, Retinal Vessels pathology, Retinal Vessels physiopathology, Vascular Stiffness physiology
- Abstract
Background: The fundoscopic examination of hypertensive patients, an established hypertension-related target organ damage, tends to be underutilized in clinical practice. We sought to investigate the relationship between retinal alterations and aortic stiffness, an independent predictor of cardiovascular morbidity and mortality., Methods: Our population consisted of 197 consecutive essential hypertensive patients (age 60 ± 13 years, 115 females) without overt cardiovascular disease. All subjects underwent fundoscopy examination and were distributed to four groups according to Scheie's grading system. Aortic stiffness was evaluated by carotid-femoral pulse wave velocity with a validated device (Complior)., Results: The four groups (Scheie's grades 0-3: including 24, 75, 74, 24 patients respectively) did not differ with regard to age, gender and their metabolic profile. Patients with higher Scheie's category had higher values of pulse wave velocity (8.2 ± 1.5, 8.9 ± 1.7, 9.3 ± 1.8, 9.8 ± 2.1m/s respectively, p=0.001). Multivariable regression analysis showed that age, fundus classification and systolic arterial pressure were independent determinants of pulse wave velocity., Conclusion: Hypertensive subjects exhibit a progressive stiffening of the aorta in parallel with the progression of retinal alterations according to Scheie's scale. Further studies are needed to clarify involved pathophysiological mechanisms and explore possible causal relationships., (Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
28. A 31 year old woman with essential hypertension grade III and branch retinal vein occlusion with homozygous C677T MTHFR hyperhomocysteinemia and high Lp(a) levels.
- Author
-
Katsi V, Tousoulis D, Chatzistamatiou E, Androulakis E, Moustakas G, Skiadas I, Tsioufis C, Antoniades C, Stefanadis CI, and Kallikazaros IE
- Subjects
- Adult, Antihypertensive Agents therapeutic use, Aspirin therapeutic use, Female, Humans, Hyperhomocysteinemia metabolism, Hypertension drug therapy, Lipoprotein(a) blood, Point Mutation, Retinal Vein Occlusion drug therapy, Vitamins therapeutic use, Hyperhomocysteinemia complications, Hyperhomocysteinemia genetics, Hypertension complications, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Retinal Vein Occlusion etiology
- Abstract
We report a 31-year old woman with essential hypertension grade III and history of branch retinal vein occlusion in the setting of hyperhomocysteinemia due to homozygous MTHFR gene mutation and elevated Lp(a). The patient was treated successfully with antihypertensive treatment, acetylsalicylic acid and multivitamin complex supplementation., (Copyright © 2008 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
29. Health Related Quality of Life and Cardiovascular Risk Factors.
- Author
-
Kontoangelos, Konstantinos, Soulis, Dimitris, Soulaidopoulos, Stergios, Antoniou, Christos Konstantinos, Tsiori, Sofia, Papageorgiou, Christos, Martinaki, Sofia, Mourikis, Iraklis, Tsioufis, Konstantinos, Papageorgiou, Charalabos, and Katsi, Vasiliki
- Subjects
RISK assessment ,HEALTH status indicators ,CARDIOVASCULAR diseases ,HYPERLIPIDEMIA ,CORONARY disease ,PSYCHIATRY ,CARDIOLOGY ,OUTPATIENT services in hospitals ,HYPERTENSION ,SMOKING ,FUNCTIONAL assessment ,QUESTIONNAIRES ,CARDIOVASCULAR diseases risk factors ,HEALTH surveys ,CARDIOPULMONARY system ,QUALITY of life ,EXERCISE tolerance ,PSYCHOMETRICS ,EXERCISE tests ,DIABETES ,OBESITY ,DISEASE complications - Abstract
Cardiovascular diseases (CVD) is associated with deteriorating of quality of life (QOL) and exercise capacity (EC) but less is known on how EC interplays with QOL. The present study explores the relationship between quality of life and cardiovascular risk factors in people who present in cardiology clinics. A total of 153 adult presentations completed the SF-36 Health Survey and provided data for hypertension, diabetes mellitus, smoking, obesity, hyperlipidemia and history of coronary heart disease. Physical capacity was assessed by treadmill test. were correlated with the scores of the psychometric questionnaires. Participants with longer duration on treadmill exercise score higher on the scale of physical functioning. The study found that treadmill exercise intensity and duration were associated with improved scores in dimensions of the physical component summary and the physical functioning of SF-36, respectively. The presence of cardiovascular risk factors is related to a decreased quality of life. Patients with cardiovascular diseases should undergo particularly detailed analysis of the quality of life along with specific mental factors such as depersonalization and posttraumatic stress disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. The Molecular Basis of the Augmented Cardiovascular Risk in Offspring of Mothers with Hypertensive Disorders of Pregnancy.
- Author
-
Svigkou, Asimenia, Katsi, Vasiliki, Kordalis, Vasilios G., and Tsioufis, Konstantinos
- Subjects
- *
PREECLAMPSIA , *HYPERTENSION , *HYPOTHALAMIC-pituitary-gonadal axis , *PREGNANCY complications , *ENDOTHELIUM diseases , *CARDIOVASCULAR diseases risk factors - Abstract
The review examines the impact of maternal preeclampsia (PE) on the cardiometabolic and cardiovascular health of offspring. PE, a hypertensive disorder of pregnancy, is responsible for 2 to 8% of pregnancy-related complications. It significantly contributes to adverse outcomes for their infants, affecting the time of birth, the birth weight, and cardiometabolic risk factors such as blood pressure, body mass index (BMI), abdominal obesity, lipid profiles, glucose, and insulin. Exposure to PE in utero predisposes offspring to an increased risk of cardiometabolic diseases (CMD) and cardiovascular diseases (CVD) through mechanisms that are not fully understood. The incidence of CMD and CVD is constantly increasing, whereas CVD is the main cause of morbidity and mortality globally. A complex interplay of genes, environment, and developmental programming is a plausible explanation for the development of endothelial dysfunction, which leads to atherosclerosis and CVD. The underlying molecular mechanisms are angiogenic imbalance, inflammation, alterations in the renin–angiotensin–aldosterone system (RAAS), endothelium-derived components, serotonin dysregulation, oxidative stress, and activation of both the hypothalamic–pituitary–adrenal axis and hypothalamic–pituitary–gonadal axis. Moreover, the potential role of epigenetic factors, such as DNA methylation and microRNAs as mediators of these effects is emphasized, suggesting avenues for future research and therapeutic interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Aspirin vs Heparin for the Prevention of Preeclampsia
- Author
-
Katsi, Vasiliki, Kanellopoulou, Theoni, Makris, Thomas, Nihoyannopoulos, Petros, Nomikou, Efrosyni, and Tousoulis, Dimitrios
- Published
- 2016
- Full Text
- View/download PDF
32. Arterial Hypertension and Health-Related Quality of Life.
- Author
-
Katsi, Vasiliki, Kallistratos, Manolis S., Kontoangelos, Konstantinos, Sakkas, Pavlos, Souliotis, Kyriakos, Tsioufis, Costas, Nihoyannopoulos, Petros, Papadimitriou, George N., and Tousoulis, Dimitris
- Subjects
HYPERTENSION ,THERAPEUTICS ,QUALITY of life ,PUBLIC health - Abstract
Purpose: To investigate the effect of awareness of arterial hypertension on quality of life in hypertensive patients in Greece. Materials and methods: This was a prospective observational study that included 189 aware hypertensive patients on treatment with antihypertensive therapy. Patients were ambulatory men or women =18 years old, with diagnosed essential hypertension. The administration and fulfillment of the questionnaires was given at the outpatient hypertensive clinic starting with the SF-36 and continuing with the BDI-I test. Results: The mean BDI score was 9.9 ± 6.9, and 58, 25, 8.9, and 7.3% were identified as without, with minimal, moderate, and 0.8% with severe depression, respectively. The mean score for physical component summary (PCS-36) was 48.9 ± 7.6, and the mean score for mental component summary (MCS-36) was 46.0 ± 10.6. The stage of hypertension was not an independent predictor for any of the SF-36 dimensions. Dippers had not different levels of health-related quality of life (HRQOL) as compared with non-dippers. LV hypertrophy was associated with lower scores on bodily pain (p < 0.05) and kidney failure was associated with lower scores on general health perception (p < 0.05). Female gender, increased age, and the presence of COPD were independently associated with lower physical and mental health scores (p < 0.05). Score on BDI independently correlated with all dimensions of SF-36, indicating that greater depression levels are associated with lower levels of HRQOL. Conclusion: The stage as well as awareness of arterial hypertension does not affect physical and mental health. The fact that arterial hypertension per se is not a symptomatic disease may explain these results at least in patients with uncomplicated hypertension. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
33. The Role of Statins in Prevention of Preeclampsia: A Promise for the Future?
- Author
-
Katsi, Vasiliki, Georgountzos, Georgios, Kallistratos, Manolis S., Zerdes, Ioannis, Makris, Thomas, Manolis, Athanasios J., Nihoyannopoulos, Petros, and Tousoulis, Dimitris
- Subjects
STATINS (Cardiovascular agents) ,PREECLAMPSIA prevention ,HYPERTENSION - Abstract
Preeclampsia has been linked to high morbidity and mortality during pregnancy. However, no efficient pharmacological options for the prevention of this condition are currently available. Preeclampsia is thought to share several pathophysiologic mechanisms with cardiovascular disease, which has led to investigations for the potential role of statins (HMG CoA reductase inhibitors) in its prevention and early management. Pravastatin seems to have a safer pharmacokinetic profile compared to other statins, however, the existing preclinical evidence for its effectiveness in preeclampsia treatment has been mostly restricted to animal models. This review aims to summarize the current data and delineate the potential future role of statins in the prevention and management of preeclampsia. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
34. Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study.
- Author
-
Georgiopoulos, Georgios, Katsi, Vasiliki, Oikonomou, Dimitrios, Vamvakou, Georgia, Koutli, Evangelia, Laina, Aggeliki, Tsioufis, Constantinos, Nihoyannopoulos, Petros, Tousoulis, Dimitrios, Angulo, Javier, and Gaspari, Tracey
- Subjects
CARDIOVASCULAR disease treatment ,ANTIHYPERTENSIVE agents - Abstract
Background: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive subjects with diabetes mellitus type II (DMII). Methods: Under this prism, we performed a systematic review of the literature for all relevant articles in order to evaluate the efficacy, safety, and possible clinical role of AZL-M in hypertensive diabetic patients. Results: AZL-M was found to be more effective in terms of reducing indices of blood pressure over alternative ARBs or angiotensin-converting enzyme (ACE) inhibitors with minimal side effects. Preclinical studies have established pleiotropic effects for AZL-M beyond its primary antihypertensive role through differential gene expression, up-regulation of membrane receptors and favorable effect on selective intracellular biochemical and pro-atherosclerotic pathways. Conclusion: Indirect but accumulating evidence from recent literature supports the efficacy and safety of AZL-M among diabetic patients. However, no clinical data exist to date that evince a beneficial role of AZL-M in patients with metabolic disorders on top of its antihypertensive effect. Further clinical studies are warranted to assess the pleiotropic cardiometabolic benefits of AZL-M that are derived from preclinical research. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
35. Exploring the association of retinopathy with metabolic syndrome, ambulatory blood pressure and cardiac remodeling in hypertensive individuals
- Author
-
Katsi, Vasiliki, Souretis, Georgios, Alexopoulos, Nikolaos, Vlachopoulos, Charalambos, Dagalaki, Ioanna, Sideris, Skevos, Tousoulis, Dimitris, Stefanadis, Christodoulos, and Kallikazaros, Ioannis
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.